A number of surveys confirm that people living with HIV are interested in finding a way to control HIV infection without taking medicines every day.
The HIVACAR project is aimed at investigating some strategies that could help better understand how to develop this kind of interventions.
It is therefore crucial that people living with HIV and the public at a large can access easy-to-understand information about the project.
In this section of the website, you will find:
- A description of the HIVACAR project, including information on the clinical trial and on the psychosocial research
- Resources on HIV/AIDS cure strategies research
- Contact information
Description of the HIVACAR project
The HIVACAR project has two main objectives:
- Investigating new therapeutic alternatives to “cART for life” (combination antiretroviral therapy)
- Analysing individual and public health limitations associated with the standard of care.
This will be done by conducting two studies:
- A clinical trial investigating a patient-tailored, safe, affordable and scalable, innovative intervention that potentially could help controlling HIV infection even without antiretroviral treatment;
- A survey among people living with HIV (PLHIV) investigating how much they know about and what they expect from the research for an intervention that could help controlling HIV infection without taking medicines every day.
The clinical trial
This will be a pivotal study involving people living with HIV with specific characteristics. By “pivotal” we mean that, since this therapeutic intervention has not been studied before, the trial will only involve few participants and will take into particular consideration all the issues related to the participants’ safety.
The therapeutic intervention that the trial will investigate is an immune-based strategy. “Immune-based” means that this will involve treatments aimed at improving the response of participants’ immune system against HIV.
The immune-based strategy investigated in the HIVACAR trial will be a combination of these three treatments:
- A therapeutic vaccine: this is a compound that is supposed to stimulate immune-system, helping it fight against HIV. A stronger immune response should be able to avoid spread of HIV infection in the body. The HIVACAR study will compare two different therapeutic vaccines.
- A broadly neutralizing antibody: antibodies are part of the immune system and they fight against infectious agents. This antibody is called “broadly neutralising” because it is supposed to stop the replication of several types of HIV, since a single person can be infected with many different variants of the virus.
- A latency reversing agent: HIV hides inactive in some cells; these cells do not look like the cells infected with an active HIV and therefore are not recognised by the immune system or antiretroviral drugs. In order to get rid of that inactive HIV, it should be “waken up” from its latent status. This compound is called “latency reversing agent” because it is supposed to reactivate HIV from its latent status.
The Psychosocial study
Participants in the clinical study and the community of PLHIV at large will be asked to answer a questionnaire designed to investigate:
- How much they know about the risks and the benefits of taking part to a clinical study investigating a strategy to control HIV infection without taking medicines every day, and how they think information about this should be given.
- How they think their lives would be changed if they could be able to control HIV infection without taking medicines, and if this would impact also how they take care of their health.
- How they think society as a large could change the way people living with HIV are looked at if they could control the virus without taking medications.
Alongside this survey, another analysis will investigate how economic resources could be allocated differently if HIV infection could be controlled without medications.
The HIVACAR project is developed with the contribution of representatives of the community of people living with HIV in Europe. The European AIDS Treatment Group (EATG) is a partner of the HIVACAR consortium and is responsible for: assessing, from the participants’...
Currently, over 36 million people worldwide are infected with HIV, most of them living in developing countries1. In 2014, 1.2 million people died of AIDS-related illnesses…
Resources on HIV/AIDS cure strategies research
|Cure glossary, guide and resources||DARE||HIV/AIDS Cure Research introduction and resource guide||Link||Glossary introduction to the issues involved in research related to curing HIV infection|
|Cure glossary, guide and resources||DARE||Introducción a la Investigación sobre la Cura para el VIH/SIDA-2017||Link||Spanish version of the cure glossary|
|Cure/ Therapeutic vaccines||Avac||Cure fact sheet||Link||Basic information on HIV cure research|
|Cure/ Therapeutic vaccines||Avac||CUREiculum||Link||A suite of tools that provides simple, accessible information on HIV cure research, including information on participation in HIV cure trials, informed consent and ethics of HIV cure research,|
|Cure/ Therapeutic vaccines||i-Base||The HIV Cure puzzle||Link||Easy to read guide on the cure|
|Cure/vaccines||Avac||Avac database||Link||Offers a search option on several topics regarding vaccines, cure|
|Research and development||TAG||Research toward a cure and immune-based therapy||Link||Offers the most recent data on the most promising HIV cure research scientific programmes|
|Therapeutic vaccines||EATG/NAM||Steps report||Link||European cure review including a description of the HIVACAR project|
|Treatment interruption||TAG||Community recommendations for clinical research involving antiretroviral treatment interruptions||Link||Provide recommendations for PLHIV participating in studies which requires treatment interruption|
|Viral reservoirs/ Viral rebound||i-Base||ART in pictures: the viral reservoir||Link||Easy to read guide on the viral reservoirs|
Write to us to know more.
European AIDS Treatment Group, EATG: firstname.lastname@example.org